Lithium decreases plasma adiponectin levels in bipolar depression

Márcio Gerhardt Soeiro-de-Souza, Philip W. Gold, Andre R. Brunoni, Rafael T. de Sousa, Marcus V. Zanetti, André F. Carvalho, Wagner Farid Gattaz, Rodrigo Machado-Vieira, Ant Ônio Lúcio Teixeira

Producción científica: Articlerevisión exhaustiva

36 Citas (Scopus)


Lithium, a first line treatment for bipolar disorder (BD), has been associated with significant weight gain, but the mechanisms underlying this phenomenon are still unclear. It has been suggested that changes in production/release of adipokines - molecules secreted by adipose tissue presenting anti-inflammatory (adiponectin) and pro-inflammatory (leptin, resistin) properties - might be implicated. Adiponectin, resistin and leptin were assessed in 25 acutely depressed BD individuals (88% medication-free and 68% treatment-naive) at baseline and after 6 weeks of lithium therapy, and in 23 healthy controls matched by age. The 21-item Hamilton Depression Rating Scale was used to assess depression severity. Levels of adiponectin significantly decreased after lithium monotherapy, while the levels of resistin and leptin remained stable after the follow-up period. Adipokine levels during depressive episodes in BD did not differ compared to controls. Pretreatment levels of leptin were higher in remitters and changes in resistin levels were negatively correlated to improvement of depressive symptoms with lithium. Our findings shed light in this pathophysiological process, which might be associated with metabolic syndrome, inflammation and other medical comorbidities in BD.

Idioma originalEnglish (US)
Páginas (desde-hasta)111-114
Número de páginas4
PublicaciónNeuroscience Letters
EstadoPublished - abr 3 2014
Publicado de forma externa

ASJC Scopus subject areas

  • General Neuroscience


Profundice en los temas de investigación de 'Lithium decreases plasma adiponectin levels in bipolar depression'. En conjunto forman una huella única.

Citar esto